Gold stocks generally rose before the market opened, with Harmony Gold rising more than 4%

Gelonghui, May 20 | Before the U.S. stock market opened, Harmony Gold and Gold Fields rose more than 4%, and AngloGold Ashanti and Cordelen Mining rose more than 3%.

Gelonghui, May 20 | U.S. stocks pre-market. Harmony Gold and Gold Fields rose more than 4%. AngloGold Ashanti and Cordelen Mining rose more than 3%.

Like (0)
Previous May 20, 2024 4:56 pm
Next May 20, 2024 4:56 pm

Related posts

  • Fengyuzhu (603466.SH): Net loss in the first quarter was 15.0139 million yuan

    Gelonghui April 25丨Fengyuzhu (603466.SH) released its first quarter report for 2024. During the reporting period, the company achieved operating income of 295 million yuan, a year-on-year decrease of 30.29%; the net loss attributable to shareholders of the listed company was 15.0139 million yuan. ; The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 15.112 million yuan; the basic loss per share was 0.01 yuan.

    US Stocks Focus April 25, 2024
  • Broker’s call: JSW Steel (Buy)

    Target: ₹1,070 CMP: ₹915.15 JSW Steel posted a consolidated revenue of ₹46,300 crore (-2% y-o-y/ +10 per cent q-o-q ; in line) in Q4-FY24. ASP stood at ₹68,750/t (-4 per cent y-o-y/-2 per cent q-o-q) vs. our est. of ₹67,507/t. Combined crude steel production was 6.79mt (+3 per cent y-o-y/-1 per cent q-o-q), while steel sales came in at 6.73mt (+3 per cent y-o-y/+12 per cent q-o-q) with capacity utilisation of 93 per cent at the Indian operations. JSTL India operations reported the highest ever VASP sales, up 5 per cent y-o-y (about 62 per cent share of total sales). During FY24, revenue grew 5 per cent to ₹1,75,000 crore led by robust volume growth. EBITDA/APAT stood at ₹28200 crore/₹9,000 crore. Consolidated crude steel production and sales volume stood at 26.4mt and 25mt, respectively. Going forward, we expect JSTL’s domestic volumes to be robust with increasing capacities, a better product mix, and export opportunities. Moreover, with stable pricing, softened coal costs, and improving operational efficiencies, we expect its EBITDA/t to improve going forward. We raise our revenue/EBITDA estimates by 2/5…

    US Stocks Focus May 23, 2024
  • Catfish is coming! Tesla’s Shanghai Energy Storage Gigafactory gets permission to start construction

    Tesla’s first energy storage Gigafactory project outside the United States completed the issuance of a construction permit today

    US Stocks Focus May 13, 2024
  • European stocks collectively opened lower, with the Stoxx Europe 50 index falling 0.80%

    The European Stoxx 50 index fell 0.80%, the German DAX index fell 0.83%, the British FTSE 100 index fell 0.78%, and the French CAC 40 index fell 0.62%.

    US Stocks Focus May 24, 2024
  • From new productive forces to breakthroughs in foreign trade, experts: These elements inject new vitality into China’s economy

    On April 23, the China Journalists Association held a press teahouse in Shanghai for the first time. Five experts from the Institute of World Economics and Politics, Chinese Academy of Social Sciences, interpreted the Chinese economy around current hot topics, such as new productivity and foreign investment.

    US Stocks Focus April 25, 2024
  • The vaccine market is turbulent, and Zhifei Biotech’s “big brother” status is difficult to maintain

    For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…

    US Stocks Focus April 25, 2024